目的：探讨单项TCT检查、HC2-HPV检测及TCT联合HC2-HPV检测在宫颈癌筛查中的优缺点及临床意义。方法：随机选取门诊妇产科患者500例，对其均进行单项TCT、HC2-HPV监测及组织病理检查，分析单项TCT检查、HC2-HPV检测及TCT联合HC2-HPV检测与组织病理检查的符合情况，以明确单项TCT检查、HC2-HPV检测在宫颈癌筛查中存在的不足，以及TCT联合HC2-HPV检测在宫颈癌筛查中的优越性。诊断标准采用TBS分级系统。结果：单项TCT检测及HC2-HPV检测均存在假阴性和假阳性，结果显示：TCT检测结果细胞异型性越大、分级越高，HC2-HPV阳性率越高；组织病理检查细胞异型增生越明显，HC2-HPV阳性率越高；而将TCT检测及HC2-HPV检测联合起来，宫颈癌筛查的假阴性率明显降低，从而提高了与组织病理检查的符合率。结论：将TCT检查及HC2-HPV检测联合应用，能提高妇科患者宫颈癌筛查与组织病理检查的符合率和病理诊断的正确率，从而避免因误诊给患者带来过度治疗，或因漏诊延误患者的最佳治疗时机。

[1] 隋霜,玛依努尔·尼亚孜.人乳头瘤病毒检测与宫颈癌筛查的研究进展[J].医学综述,2009,5(15):694-696.
[2] 廖丹梅,黄明春,李惠珍等.TCT联合HPV-DNA检测在宫颈病变中的诊断价值[J].广西医科大学学报,2008,(01):51-53.
[3] CHENG W F,LEE C N,SU Y N,et a1.Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations[J].Immunology,2005,115(1):136-149.
[4] BORY J P,CUCHEROUSSET J,LORENZATO M,et a1.Recurrent human papillo-mavims infection detected with the hybrid capture Ⅱ assay selects women with normal cervical smears at risk for developing high grade cervical lesions:a longitudinal study of 3091 women[J].Int J Cancer,2002,102(5):519-525.
[5] 兴云,赵蔚,李桂军,等.细胞学联合人乳头瘤病毒杂交捕获检测在宫颈上皮内瘤样病变筛查中应用[J].中华医学杂志,2012,92(35):2503-2505.
[6] WASHIYA K,NAKAMURA M,MIZUKI Y,MOTOI M,et a1.Discriminating analysis of atypical squamous cells of undetermined significance of the uterine cervix using nuclear three-dimensional analysis[J].Acta Cytol,2014,58(1):96-102.
[7] 赵志新,刘建,金志荣,等.蒙古族患者子宫颈TCT异常病例与HPV-DNA及病理组织学诊断结果的比较分析[J].中国实用医药,2012,7(24):156-158.
[8] SCADNCI I C,GARCIA F A,KOBETZ E,et a1.Cervical cancer prevention:flew tools and old barriers[J].Cancer,2010,116(11):2531-2542.
[9] NONN M,SCHINZ M,ZUMBACH K,et a1.Dendritic cell-based tumor vaccine for cervical cancer I:in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7[J].J Cancer Res Clin Oncol,2003,129(9):511-520.
[10] PETT M R,HERDMAN M T,PALMER R D,et a1.Selection of cervical keratinocytes containing integrated HPV16 associates with episome loss and an endogenous antiviral response[J].Proc Natl Acad Sci USA,2006,103(10):3822-3827.
[11] GUO Y L,YOU K,GENG L,et a1.Use of high-risk human papillomavirus DNA testing to deal with atypical squamous cells undetermined significance and low squamous intraepithelial lesion[J].Beijing Da Xue Xue Bao,2006,38(5):480-482.
[12] JURIC D,MAHOVLIC V,RAJHVAJN S,et a1.Liquid-based cytology--new possibilities in the diagnosis of cervical lesions[J].Coll Antropol,2010,34(1):19-24.
[13] CORNELISON T L.Human papillomavirus genotype 16 vaccines for cervical cancer prophylaxis and treatment[J].Curr Opin Oncol,2000,12(5):466-473.
[14] STANLEY M A.Progress in prophylactic and therapeutic vaccines for human papillomavirus infection[J].Expert Rev Vaccines,2003,2(3):381-389.
[15] EVANS M F,ADAMSON C S,PAPILLO J L,et a1.Distribution of human papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes[J].Cancer,2006,106(5):1054-1064.
[16] BERKOWITZ R P.2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors[M].Obstet Gynecol.2013,122(2 Pt 1):393.